PTGX · Protagonist Therapeutics, Inc
$155.03
-0.07 (-0.05%)
At close · Aug 17
Market Cap
$10.04B
Shares
64.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$155.10
Open$150.23
Day$149.17–155.53
52W close$54.99–155.10
Avg vol 30d627K
Short int7.5M · 11.7% float · 14.2d
Short vol75%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Mar 21, 2027
Est · unconfirmed
· in 31 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+54%
above
Price vs 50-day avg
+20%
above
RSI (14)
70
overbought
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+79%
trailing
YTD return
+78%
this year
Relative strength
+65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $129 › 200d $101 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.66% of float · ▼ -9.0% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
341 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
−89%
Y/Y
EPS growth
−148%
Y/Y
Free cash flow
$56.1M
Valuation
P/E 150.6
rich
Balance sheet
$118.6M
net cash
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+54%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
70
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $129 › 200d $101 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +61 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.66% of float · ▼ -9.0% MoM · 14.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
341 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $55
Now $155 · 100%
Range high $155
vs 200-day avg +54%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTGX
this stock
Protagonist Therapeutics, Inc
|
$10.04B | +77.6% | -89.4% | 150.6 | 11.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTGX | +6.3% | +10.1% | +79.1% | +13.5% | +77.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +5.9% | +5.6% | +65.4% | +9.6% | +63.7% |
Key facts
CIK
1377121
CUSIP
74366E102
13F (30d)
326 filings
319 filers
Visit website
Investor relations